Kezar Life Sciences Inc (DE:2KZ0)
FRANKFURT:2KZ0
Total Valuation
Kezar Life Sciences has a market cap or net worth of €46.63M. The enterprise value is -€15.08M.
Market Cap€46.63M
Enterprise Value-€15.08M
Share Statistics
Kezar Life Sciences has 7,371,527 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,371,527
Owned by Insiders19.30%
Owned by Institutions48.98%
Financial Efficiency
Kezar Life Sciences’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is -72.20%.
Return on Equity (ROE)-0.80
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-72.20%
Return on Capital Employed (ROCE)-0.75
Revenue Per Employee0.00
Profits Per Employee-1.02M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kezar Life Sciences is ―. Kezar Life Sciences’s PEG ratio is -0.00145.
PE Ratio―
PS Ratio0.00
PB Ratio0.66
Price to Fair Value0.66
Price to FCF-0.89
Price to Operating Cash Flow-1.04
PEG Ratio-0.00145
Income Statement
In the last 12 months, Kezar Life Sciences had revenue of 0.00 and earned -56.03M in profits. Earnings per share was -7.66.
Revenue0.00
Gross Profit-897.00K
Operating Income-52.27M
Pretax Income-56.03M
Net Income-56.03M
EBITDA-51.37M
Earnings Per Share (EPS)-7.66
Cash Flow
In the last 12 months, operating cash flow was -51.78M and capital expenditures -8.00K, giving a free cash flow of -51.78M billion.
Operating Cash Flow-51.78M
Free Cash Flow-51.78M
Free Cash Flow per Share-7.03
Dividends & Yields
Kezar Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change64.92%
50-Day Moving Average5.53
200-Day Moving Average4.59
Relative Strength Index (RSI)61.98
Average Volume (3m)111.00
Important Dates
Kezar Life Sciences upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Kezar Life Sciences as a current ratio of 11.52, with Debt / Equity ratio of 3.32%
Current Ratio11.52
Quick Ratio11.52
Debt to Market Cap0.00
Net Debt to EBITDA1.35
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kezar Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kezar Life Sciences EV to EBITDA ratio is 0.46, with an EV/FCF ratio of 0.45.
EV to Sales0.00
EV to EBITDA0.46
EV to Free Cash Flow0.45
EV to Operating Cash Flow0.45
Balance Sheet
Kezar Life Sciences has €71.88M in cash and marketable securities with €2.33M in debt, giving a net cash position of €69.55M billion.
Cash & Marketable Securities€71.88M
Total Debt€2.33M
Net Cash€69.55M
Net Cash Per Share€9.44
Tangible Book Value Per Share€9.58
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kezar Life Sciences is €6.23, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target€6.23
Price Target Upside-1.09% Downside
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―